Showing 1 - 5 results of 5 for search 'Rebecca Wiggins', query time: 0.04s Refine Results
  1. 1
    LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis [version 1; peer review: 2 approved]

    LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis [version 1; peer review: 2... by Ahmed Musa, Charles Lacey, Brima Younis, El Tahir Khalil, Rebecca Wiggins, Mohamed Osman, Paul Kaye, Ada Keding

    Published 2022-08-01
    Get full text
    Article
  2. 2
    Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment.

    Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment. by Alejandro Arenas-Pinto, Alan Winston, Wolfgang Stöhr, John Day, Rebecca Wiggins, Say Pheng Quah, Jonathan Ainsworth, Sue Fleck, David Dunn, Alex Accoroni, Nicholas I Paton, PIVOT Trial Team

    Published 2014-01-01
    Get full text
    Article
  3. 3
    A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.

    A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH. by Mohamed Osman, Anoop Mistry, Ada Keding, Rhian Gabe, Elizabeth Cook, Sarah Forrester, Rebecca Wiggins, Stefania Di Marco, Stefano Colloca, Loredana Siani, Riccardo Cortese, Deborah F Smith, Toni Aebischer, Paul M Kaye, Charles J Lacey

    Published 2017-05-01
    Get full text
    Article
  4. 4
    A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis

    A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis by Brima M. Younis, Rebecca Wiggins, Eltahir A.G. Khalil, Mohamed Osman, Francesco Santoro, Chiara Sonnati, Ada Keding, Maria Novedrati, Giorgio Montesi, Ali Noureldein, Elmukashfi T.A. Elmukashfi, Ala Eldin Mustafa, Mohammed Alamin, Mohammed Saeed, Khalid Salman, Ahmed J. Suliman, Amin E.A. Musa, Alison M. Layton, Charles J.N. Lacey, Paul M. Kaye, Ahmed M. Musa

    Published 2024-09-01
    Get full text
    Article
  5. 5
    Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial

    Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial by Deborah Watson-Jones, ProfPhD, John Changalucha, MSc, Hilary Whitworth, PhD, Ligia Pinto, PhD, Paul Mutani, MD, Jackton Indangasi, MSc, Troy Kemp, PhD, Ramadhan Hashim, BSc, Beatrice Kamala, Dip, Rebecca Wiggins, PhD, Twaib Songoro, BA, Nicholas Connor, MSc, Gladys Mbwanji, MSc, Miquel A Pavon, PhD, Brett Lowe, MSc, Devis Mmbando, BSc, Saidi Kapiga, ProfPhD, Philippe Mayaud, ProfMD, Silvia de SanJosé, MD, Joakim Dillner, ProfPhD, Richard J Hayes, ProfDSc, Charles J Lacey, ProfMD, Kathy Baisley, MSc

    Published 2022-10-01
    Get full text
    Article

Search Tools: